IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
HPV in Adolescents
This study has been completed.
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Thai Red Cross AIDS Research Centre
Chulalongkorn University
South East Asia Research Collaboration with Hawaii
We Understand Group
TREAT Asia
Information provided by (Responsible Party):
The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier:
NCT01788852
First received: February 7, 2013
Last updated: March 30, 2015
Last verified: March 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will assess the prevalence of HPV infection in perinatally HIV-infected adolescents, intraepithelial neoplasia, and E6E7 biomarker at cervical and anal sites.
| Condition |
|---|
| HPV Infection Cervical/Anal Dysplasia |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents |
Resource links provided by NLM:
Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:
Primary Outcome Measures:
- HPV infection [ Time Frame: 48 weeks ]Prevalence of cervical and anal HPV infection and of oncogenic subtypes, among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIv-negative adolescents
Secondary Outcome Measures:
- intraepithelial neoplasia [ Time Frame: 48 weeks ]Prevalence of intraepithelial neoplasia among the three study groups and in male and female subjects
- E6/E7 [ Time Frame: 48 weeks ]
Prevalence of detected E6/E7 biomarker among the tree study groups and in male and female subjects.
Correlation between detected E6/E7 and presence of HPV infection and/or intraepithelial neoplasia Association between HAART use, CD4 counts, plasma HIV RNA level and HIV clinical staging with HPV infection, intraepithelial neoplasia and E6/E7 detection
- HPV vaccine [ Time Frame: 48 weeks ]Proportion of adolescents who would benefit from the current preventive vaccine (i.e. those who have not been infected with oncogenic HPV subtypes 16 and 18)
Biospecimen Retention: Samples With DNA
Cervical and anal pap smears specimens will be used for HPV typing. Blood will be collected for STI and immune response to HPV/HIV testing
| Enrollment: | 27 |
| Study Start Date: | December 2010 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Perinatally HIV-infected adolescents
Perinatally HIV-infected adolescents
|
|
behaviorally HIV-infected adolescents
behaviorally HIV-infected adolescents
|
|
HIV negative adolescents
HIV negative adolescents
|
Detailed Description:
Human Papillomavirus (HPV) is the most common sexually transmitted disease and it causes cervical and anal cancer. Prevalence and incidence of HPV infection among young adults who are sexually experienced is high. No data exist for HIV-positive adolescents in regards to HPV infection, cervical and anal intraepithelial neoplasia. This study will compare the prevalence of HPV infection, intraepithelial neoplasia and E6/E7 biomarker at cervical and anal sites among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIV-negative adolescents.
Eligibility| Ages Eligible for Study: | 12 Years to 24 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
A total of 60 sexually active adolescents (perinatally and behaviorally HIV-infected adolescents, HIV negative adolescents) aged 12-24 will be recruited from the HIV-NAT and TRC Anonymous Clinic
Criteria
Inclusion Criteria:
- Perinatally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time and history of maternal HIV infection)
- behaviorally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time after sexual debut without history of maternal HIV infection)
- female with vaginal or receptive anal intercourse with a male OR male with receptive rectal intercourse with another male
- Signed informed consent. Volunteers aged 12-17 years can decide whether they wish for their parents to consent for their participation. Due to the confidential nature of the issues being studied, parental consent may be exempted
Exclusion Criteria:
- Have any conditions that may interfer with subjects' ability to understand and consent to the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01788852
Please refer to this study by its ClinicalTrials.gov identifier: NCT01788852
Locations
| Thailand | |
| Department of Pediatrics, Chulalongkorn University | |
| Bangkok, Thailand, 10330 | |
| HIV-NAT | |
| Bangkok, Thailand, 10330 | |
| Thai Red Cross - Anonymous Clinc | |
| Bangkok, Thailand, 10330 | |
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Thai Red Cross AIDS Research Centre
Chulalongkorn University
South East Asia Research Collaboration with Hawaii
We Understand Group
TREAT Asia
Investigators
| Principal Investigator: | Jintanat Ananworanich, MD, PhD | The HIV Netherlands Australia Thailand Research Collaboration |
| Principal Investigator: | Nittaya Phanuphak, MD | Thai Red Cross AIDS Research Centre |
More Information
Additional Information:
| Responsible Party: | The HIV Netherlands Australia Thailand Research Collaboration |
| ClinicalTrials.gov Identifier: | NCT01788852 History of Changes |
| Other Study ID Numbers: |
HIV-NAT 139 |
| Study First Received: | February 7, 2013 |
| Last Updated: | March 30, 2015 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
HPV HIV cervical/anal dysplasia intraepithelial neoplasia |
E6/E7 biomarker perinatally HIV-infected adolescents behaviorally HIV-infected adolescents anal and pap smear |
ClinicalTrials.gov processed this record on August 16, 2017